

Aus dem Max-Delbrück-Centrum für Molekulare Medizin Berlin

DISSERTATION

**Microglia – The source of insanity?  
Investigating the role of microglial cells in a developmental  
rodent model of schizophrenia**

zur Erlangung des akademischen Grades  
Doctor of Philosophy (PhD)

vorgelegt der Medizinischen Fakultät  
Charité – Universitätsmedizin Berlin

von

**Daniele Mattei**

aus Rom, Italien

Datum der Promotion: 10.03.2017

# Contents

Contents .....	1
Abstract (English) .....	2
Abstract (German) .....	4
Affidavit.....	6
Excerpt of Journal Summury List.....	8
Publication .....	10
Curriculum Vitae .....	20
List of Publications.....	23
Acknoledgment.....	25

# Abstract (English)

**Background:** During the past decade, an increasing number of studies have implicated inflammatory processes in the pathophysiology of schizophrenia. More specifically, microglial cell activation has been consistently reported in human *post mortem* and *in vivo* studies. Moreover, researchers have found that anti-inflammatory minocycline treatment has beneficial effects when given to schizophrenic patients. Nevertheless, these studies never directly addressed whether the action of this compound is directly tied to the changes in microglial cell phenotype. During my thesis, I screened the molecular basis for microglial cell phenotypic disruption in relation to the behavioral phenotype in a maternal immune activation model of schizophrenia elicited via injection of the viral mimic PolyI:C at gestational day 15. I focus here primarily on microglia derived from the hippocampus, a region strongly implicated in the symptoms manifested by schizophrenic patients. Also, I investigated how chronic minocycline treatment is acting on this model's pathological signs, from microglial cell activation, to neurogenesis and behavioral deficits.

**Methods:** combining immunohistochemical techniques and molecular biology tools along with animal behavioral analysis, I screened the nature of microglial cell disruption and its influence on animal behavior. Furthermore, I screened the effect of chronic minocycline treatment on the phenotype displayed by this model was also tested.

**Results:** I found that adult offspring of dams challenged with PolyI:C during gestation present with lower hippocampal neurogenesis, accompanied by behavioral deficits in sensorimotor gating. These changes are followed by enhanced production of pro-inflammatory cytokines by microglial cells. Chronic minocycline treatment managed to rescue most of the deficits found in the present study.

**Conclusion:** Maternal immune activation may alter microglial cell phenotype in the brains of the offspring in a long-lasting way. This could be in part responsible for the behavioral manifestations occurring in the offspring of PolyI:C challenged dams as they reach adulthood. Accordingly, anti-inflammatory minocycline treatment is able to rescue most of the observed pathological signs. It is inferable that a similar process may be in act in children of mothers who suffered influenza A infections during sensitive time windows of pregnancy. The present study adds one more piece to the

intricate puzzle picturing inflammation in the pathophysiology of schizophrenia, and prompts future research to better assess the role of microglia cells in this disease in order to find novel pharmacological targets.

# Abstract (German)

**Einleitung:** In den letzten Jahrzehnten haben verschiedene Studien inflammatorische Prozesse mit der Pathophysiologie der Schizophrenie in Verbindung gebracht. Im speziellen wurde hierbei in humanen *in vivo* und *post mortem* Versuchen eine Aktivierung von Mikroglia nachgewiesen. Darüber hinaus konnten positive Effekte durch eine anti-inflammatorische Behandlung mit Minozyklin beobachtet werden. Trotzdem wurde bisher kein direkter pharmakologischer Einfluss auf den Phänotyp von Mikrogliazellen gezeigt. In der vorliegenden Arbeit habe ich den molekularbiologischen Phänotyp dieser Zellen im Kontext des Verhaltens von Tieren in einem Immunaktivierungsmodell der Schizophrenie durch Injektion von PolyI:C während der Schwangerschaft untersucht. Der Fokus hierbei liegt auf Mikroglia aus dem Hippocampus, einer Hirnregion die in Verbindung mit dem Auftreten von Symptomen in Schizophreniepatienten steht. Weiterhin habe ich die chronischen Einflüsse einer Minozyklinbehandlung auf die Mikrogliaaktivierung, Neurogenese und Verhaltensdefizite untersucht.

**Methoden:** In einer Kombination aus immunohistochemischen und molekularbiologischen Techniken, zusammen mit Verhaltensstudien, habe ich die Veränderungen von Mikroglia und den Einfluss auf das Verhalten untersucht. Weiterhin habe ich die chronischen Einflüsse einer Minozyklinbehandlung auf den Phänotyp des PolyI:C Modells untersucht.

**Ergebnisse:** Ich fand heraus, dass adulter Nachwuchs von PolyI:C behandelten Müttern während der Schwangerschaft zu verringerter Neurogenese im Hippocampus sowie Defizite im Verhalten und der sensomotorischen Taktung. Diese Veränderungen gehen einher mit einer verstärkten Produktion von pro-inflammatorischen Zytokinen durch Mikrogliazellen. Weiterhin fand ich heraus, dass dieser Phänotyp möglicherweise durch epigenetische Veränderungen dieser Zellen hervorgerufen wird. Chronische Minozyklinbehandlung konnte das Auftreten dieser negativen Effekte verhindern.

**Fazit:** Eine Aktivierung des Immunsystems während der Schwangerschaft kann zu einer langanhaltenden Veränderung des Phänotyps von Mikrogliazellen in den Nachkommen führen. Dies könnte die Verhaltensveränderungen der Nachkommen

im Erwachsenenalter durch Polyl:C Injektionen erklären. Eine antiinflammatorische Behandlung durch Minozyklin kann diese pathologische Beobachtung verhindern. Ein vergleichbarer Effekt tritt bei Kindern durch Influenza A Infektionen von werdenden Müttern, in einer bestimmten Phase der Schwangerschaft, auf. Die vorliegende Studie trägt dazu bei ein tieferes Verständnis für die Pathophysiologie in der Schizophrenie zu bekommen. Auf Basis dieser kann zukünftige Forschung besser auf neue Therapiemöglichkeiten ausgerichtet werden.

# Affidavit

"I, Daniele Mattei certify under penalty of perjury by my own signature that I have submitted the thesis on the topic Microglia – The source of insanity? Investigating the role of microglial cells in a developmental rodent model of schizophrenia. I wrote this thesis independently and without assistance from third parties, I used no other aids than the listed sources and resources.

All points based literally or in spirit on publications or presentations of other authors are, as such, in proper citations (see "uniform requirements for manuscripts (URM)" the ICMJE [www.icmje.org](http://www.icmje.org)) indicated. The sections on methodology (in particular practical work, laboratory requirements, statistical processing) and results (in particular images, graphics and tables) correspond to the URM (s.o) and are answered by me. My interest in any publications to this dissertation correspond to those that are specified in the following joint declaration with the responsible person and supervisor. All publications resulting from this thesis and which I am author correspond to the URM (see above) and I am solely responsible.

The importance of this affidavit and the criminal consequences of a false affidavit (section 156,161 of the Criminal Code) are known to me and I understand the rights and responsibilities stated therein.

Date

Signature

## **Declaration of any eventual publications**

Daniele Mattei had the following share in the following publications:

**Mattei D\***, Djodari-Irani A\*, Hadar R, Pelz A, de Cossío LF, Goetz T, Matyash M, Kettenmann H, Winter C, Wolf SA. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behavior and Immunity 2014

Contribution in detail: Participated in experimental design and making of the experiments.

Signature, date and stamp of the supervising University teacher

---

Signature of the doctoral candidate

---



ISI Web of Knowledge<sup>SM</sup>Journal Citation Reports<sup>®</sup>

2014 JCR Science Edition

## Journal Summary List

[Journal Title Changes](#)Journals from: subject categories **NEUROSCIENCES**[VIEW CATEGORY SUMMARY LIST](#)

Sorted by: Journal Title

[SORT AGAIN](#)

Journals 21 - 40 (of 252)

Page 2 of 13

[MARK ALL](#)
[UPDATE MARKED LIST](#)

Ranking is based on your journal and sort selections.

Mark	Rank	Abbreviated Journal Title (linked to journal information)	ISSN	JCR Data <sup>1</sup>						Eigenfactor <sup>®</sup> Metrics <sup>1</sup>	
				Total Cites	Impact Factor	5-Year Impact Factor	Immediacy Index	Articles	Cited Half-life	Eigenfactor <sup>®</sup> Score	Article Influence <sup>®</sup> Score
<input type="checkbox"/>	21	BIOL CYBERN	0340-1200	4105	1.713	1.786	0.192	52	>10.0	0.00295	0.662
<input type="checkbox"/>	22	BIOL PSYCHIAT	0006-3223	40812	10.255	10.359	2.667	210	7.7	0.07948	3.553
<input type="checkbox"/>	23	BIPOLAR DISORD	1398-5647	4886	4.965	5.282	0.966	88	6.3	0.01106	1.650
<input type="checkbox"/>	24	BMC NEUROSCI	1471-2202	4101	2.665	3.066	0.398	133	5.3	0.01167	0.948
<input type="checkbox"/>	25	BRAIN	0006-8950	44379	9.196	10.418	2.422	244	8.5	0.08489	3.846
<input type="checkbox"/>	26	BRAIN BEHAV	2162-3279	368	2.243	2.229	0.205	83	2.3	0.00170	0.699
<input type="checkbox"/>	27	BRAIN BEHAV EVOLUT	0006-8977	2138	2.013	2.423	0.488	43	>10.0	0.00247	0.746
<input type="checkbox"/>	28	BRAIN BEHAV IMMUN	0889-1591	8218	5.889	5.895	1.278	205	4.7	0.02239	1.728
<input type="checkbox"/>	29	BRAIN COGNITION	0278-2626	6209	2.477	3.335	0.582	141	8.5	0.01111	1.072
<input type="checkbox"/>	30	BRAIN IMPAIR	1443-9646	210	0.809	1.167	0.000	21	5.4	0.00056	0.329
<input type="checkbox"/>	31	BRAIN INJURY	0269-9052	4685	1.808	2.126	0.305	177	8.2	0.00701	0.602
<input type="checkbox"/>	32	BRAIN LANG	0093-934X	6019	3.215	3.637	0.602	93	>10.0	0.00926	1.230
<input type="checkbox"/>	33	BRAIN PATHOL	1015-6305	3976	4.643	3.969	1.029	70	7.2	0.00814	1.325
<input type="checkbox"/>	34	BRAIN RES	0006-8993	57922	2.843	2.988	0.437	561	>10.0	0.06412	0.890
<input type="checkbox"/>	35	BRAIN RES BULL	0361-9230	8735	2.718	2.771	0.474	114	>10.0	0.01042	0.769
<input type="checkbox"/>	36	BRAIN STIMUL	1935-861X	1920	4.399	4.737	0.949	117	2.9	0.00683	1.433
<input type="checkbox"/>	37	BRAIN STRUCT FUNCT	1863-2653	2478	5.618	6.935	1.354	147	3.8	0.01071	2.435
<input type="checkbox"/>	38	BRAIN TOPOGR	0896-0267	1776	3.468	3.716	1.164	67	6.3	0.00385	1.166
<input type="checkbox"/>	39	CELL MOL NEUROBIOL	0272-4340	3224	2.506	2.134	0.527	112	6.6	0.00591	0.552
<input type="checkbox"/>	40	CEPHALALGIA	0333-1024	7097	4.891	3.736	0.926	121	7.6	0.01114	0.986

[MARK ALL](#)
[UPDATE MARKED LIST](#)

Journals 21 - 40 (of 252)

Page 2 of 13

Acceptable Use Policy  
Copyright © 2016 Thomson Reuters.




THOMSON REUTERS

Published by Thomson Reuters

# ISI Web of Knowledge<sup>SM</sup>

## Journal Citation Reports<sup>®</sup>

2014 JCR Science Edition



### Journal: BRAIN BEHAVIOR AND IMMUNITY

Mark	Journal Title	ISSN	Total Cites	Impact Factor	5-Year Impact Factor	Immediacy Index	Citable Items	Cited Half-life	Citing Half-life
<input type="checkbox"/>	BRAIN BEHAV IMMUN	0889-1591	8218	5.889	5.895	1.278	205	4.7	7.1
Cited Journal  Citing Journal  Source Data Journal Self Cites									

CITED JOURNAL DATA

CITING JOURNAL DATA

IMPACT FACTOR TREND

RELATED JOURNALS

### Journal Information

**Full Journal Title:** BRAIN BEHAVIOR AND IMMUNITY

**ISO Abbrev. Title:** Brain Behav. Immun.

**JCR Abbrev. Title:** BRAIN BEHAV IMMUN

**ISSN:** 0889-1591

**Issues/Year:** 8

**Language:** ENGLISH

**Journal Country/Territory:** UNITED STATES

**Publisher:** ACADEMIC PRESS INC ELSEVIER SCIENCE

**Publisher Address:** 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495

**Subject Categories:** IMMUNOLOGY

SCOPE NOTE

VIEW JOURNAL SUMMARY LIST VIEW CATEGORY DATA

NEUROSCIENCES

SCOPE NOTE

VIEW JOURNAL SUMMARY LIST VIEW CATEGORY DATA

#### Eigenfactor<sup>®</sup> Metrics

**Eigenfactor<sup>®</sup> Score**

0.02239

**Article Influence<sup>®</sup>**
**Score**

1.728

**Journal Rank in Categories:** JOURNAL RANKING

### Journal Impact Factor

Cites in 2014 to items published in: 2013 = 975      Number of items published in: 2013 = 185

2012 = 980      2012 = 147

Sum: 1955      Sum: 332

Calculation:  $\frac{\text{Cites to recent items}}{\text{Number of recent items}} = \frac{1955}{332} = 5.889$ 


### 5-Year Journal Impact Factor

Cites in {2014} to items published in: 2013 = 975      Number of items published in: 2013 = 185

2012 = 980      2012 = 147

2011 = 1269      2011 = 198





# Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia



Daniele Mattei<sup>a,1</sup>, Anaïs Djodari-Irani<sup>a,c,1</sup>, Ravit Hadar<sup>b</sup>, Andreas Pelz<sup>a</sup>, Lourdes Fernandez de Cossío<sup>a</sup>, Thomas Goetz<sup>b</sup>, Marina Matyash<sup>a</sup>, Helmut Kettenmann<sup>a</sup>, Christine Winter<sup>b,1</sup>, Susanne A. Wolf<sup>a,\*,1</sup>

<sup>a</sup> Max-Delbrück-Center of Molecular Medicine, Cellular Neuroscience, 13125 Berlin, Germany

<sup>b</sup> University Hospital, Clinic for Psychiatry and Psychotherapy, Experimental Psychiatry, 01307 Dresden, Germany

<sup>c</sup> Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, Charité Campus Mitte, 10117 Berlin, Germany

## ARTICLE INFO

### Article history:

Received 14 November 2013

Received in revised form 6 January 2014

Accepted 27 January 2014

Available online 7 February 2014

### Keywords:

Schizophrenia

Minocycline

Microglia

Poly I:C

Animal model

Cytokines

Neurogenesis

Sensorimotor gating

Neuroinflammation

## ABSTRACT

Adult neurogenesis in the hippocampus is impaired in schizophrenic patients and in an animal model of schizophrenia. Amongst a plethora of regulators, the immune system has been shown repeatedly to strongly modulate neurogenesis under physiological and pathological conditions. It is well accepted, that schizophrenic patients have an aberrant peripheral immune status, which is also reflected in the animal model. The microglia as the intrinsic immune competent cells of the brain have recently come into focus as possible therapeutic targets in schizophrenia.

We here used a maternal immune stimulation rodent model of schizophrenia in which polyinosinic-polycytidilic acid (Poly I:C) was injected into pregnant rats to mimic an anti-viral immune response. We identified microglia IL-1 $\beta$  and TNF- $\alpha$  increase constituting the factors correlating best with decreases in net-neurogenesis and impairment in pre-pulse inhibition of a startle response in the Poly I:C model. Treatment with the antibiotic minocycline (3 mg/kg/day) normalized microglial cytokine production in the hippocampus and rescued neurogenesis and behavior. We could also show that enhanced microglial TNF- $\alpha$  and IL-1 $\beta$  production in the hippocampus was accompanied by a decrease in the pro-proliferative TNFR2 receptor expression on neuronal progenitor cells, which could be attenuated by minocycline. These findings strongly support the idea to use anti-inflammatory drugs to target microglia activation as an adjunctive therapy in schizophrenic patients.

© 2014 Elsevier Inc. All rights reserved.

## 1. Introduction

Schizophrenia is a devastating disorder and constitutes a social and economic burden for patients as well as families and society. During the past decades, an increasing number of studies have associated schizophrenia and inflammation (Müller and Schwarz, 2010; Fineberg and Ellman, 2013). Concomitantly, microglia cells – the intrinsic immune competent cells of the brain – have been pinpointed in the pathophysiology of this neurodevelopmental disorder in both human patients and animal models of this disorder (Blank and Prinz, 2013; Fricker et al., 2013; Harry and Kraft, 2012). In a subpopulation of schizophrenic patients increased

microglial cellular density and activity has been found in post-mortem tissue and *in vivo* (Falkai et al., 1999; Steiner et al., 2006; van Berckel et al., 2008; Busse et al., 2012) as well as in animal models of schizophrenia with varying results depending on brain region and age investigated (Juckel et al., 2011; Garay et al., 2013; van den Eynde et al., 2014).

One way in which activated microglia contribute to pathology is through the production of pro-inflammatory cytokines. An imbalance in cytokine levels may trigger aberrant neurodevelopment in the fetus and lead to neuropathology and psychopathology in the adult offspring. Infection-induced increase of pro-inflammatory maternal cytokines may be one of the key events leading to enhanced risk for neuropsychiatric disorders in the offspring (Gilmore and Jarskog, 1997). Human studies revealed that increased maternal serum levels of the pro-inflammatory cytokine Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) and the chemokine Interleukin-8 (IL-8) during pregnancy are directly associated with a higher risk for schizophrenia

\* Corresponding author. Address: Max-Delbrück-Center of Molecular Medicine, Cellular Neuroscience, Robert-Rössle-Str. 10, 13125 Berlin, Germany. Tel.: +49 30 94063260; fax: +49 30 94063819.

E-mail address: [susanne.wolf@mdc-berlin.de](mailto:susanne.wolf@mdc-berlin.de) (S.A. Wolf).

<sup>1</sup> DM & ADI/CW & SAW contributed equally as first or last authors respectively.

in the progeny (Brown et al., 2004; Buka et al., 2001). In line with this finding, Mednick and colleagues reported that fetuses gestating during a viral epidemic are at elevated risk for developing schizophrenia (Mednick et al., 1988). Subsequent prospective studies have shown that maternal infections of various types increase the risk for schizophrenia in the offspring three- to sevenfold (for review see Brown and Derkits, 2010). Rodent studies have confirmed that a maternal immune response is sufficient to induce psychopathology in later life (Biscaro et al., 2012; Ozawa et al., 2006; Meyer et al., 2005; Zuckerman and Weiner, 2005; Shi et al., 2003; Abazyran et al., 2010; Zuckerman et al., 2003; Frick et al., 2013). Injection of pregnant rodents with the viral mimic polyinosinic–polycytidilic acid (Poly I:C) leads to a wide spectrum of schizophrenia-relevant behavioral deficits, such as pre-pulse inhibition of the acoustic startle response (PPI) (Gal et al., 2009; Klein et al., 2013; Kumari et al., 2008; Smith et al., 2007; Nyffeler et al., 2006; Schwarzkopf et al., 1992; for review see Yamada, 2000). Behavioral deficits are associated with schizophrenia-relevant neuropathological deficits including abnormalities in dopaminergic and glutamatergic neurotransmission (Winter et al., 2008; for review see Kirkpatrick, 2013), histopathological (Biscaro et al., 2012; Kühn et al., 2012) and structural changes (Piontkewitz et al., 2011a, 2012). The relevance of maternal Poly I:C-induced deficits to schizophrenia is further supported by the responsiveness of adult behavioral deficits to neuroleptic treatment (Piontkewitz et al., 2011b). Finally, prenatal Poly I:C-induced behavioral abnormalities exhibit the maturation delay of schizophrenia (Meyer, 2013, 2014; Feldon and Weiner, 2009), enabling the elucidation of progressive mechanisms possibly underlying behavioral manifestations as well as preventive interventions. Maternal immune stimulation is thus an excellent model to study pathophysiological and therapeutic aspects relevant to schizophrenia (Meyer and Feldon, 2012; Lipina et al., 2013; for reviews see Meyer, 2013, 2014).

Schizophrenia has the most robust clinical evidence for a disease-related reduction in grey and white matter including smaller hippocampal volume assessed in chronic schizophrenic patients (Wexler et al., 2009) and animal models (Meyer, 2013, 2014; Piontkewitz et al., 2012; Lipska, 2004). Hippocampal involvement is likely to be associated with neuropsychological impairments of schizophrenia (Harrison, 2004) as well as with its psychotic symptoms (Ewing and Winter, 2013; Floresco and Jentsch, 2011).

Hippocampal structural pathology in schizophrenia might be due to aberrant neurodevelopment and abnormal neural plasticity. One particular example of cell-based brain plasticity is the generation of new neurons in the hippocampus throughout life (Altman and Das, 1965; Eriksson et al., 1998). Neurogenesis has been linked with hippocampal-dependent function (for reviews see Deng et al., 2010; Bruel-Jungerman et al., 2007). Recently, microglial activity has been shown to be important for the homeostasis of neurogenesis, predominantly through the phagocytosis of apoptotic neuronal progenitor cells (Sierra et al., 2010) and balancing apoptotic and proliferative events via TNF- $\alpha$  signaling (Chen and Palmer, 2013). Baseline microglial activity and cytokine levels in the hippocampus are needed to maintain baseline neurogenesis while an immune response accompanied by an increase in pro-inflammatory cytokines is thought to be detrimental for neurogenesis. Consequently, anti-inflammatory drugs have been shown to ameliorate the decrease of neurogenesis caused by pro-inflammatory cytokines (for review see Kohman and Rhodes, 2013). In schizophrenic patients Miyaoka and colleagues demonstrated significant and robust clinical improvements using the tetracycline minocycline – a potent inhibitor of microglial activation (Miyaoka et al., 2008; Seki et al., 2013). Minocycline has been used successfully in some clinical trials since as an adjunctive therapy to antipsychotics for schizophrenia (for review see Dean et al., 2012). How minocycline affects microglia function *in vivo* and neurogenesis is still not fully understood.

We here evaluated the effects of minocycline treatment on neurogenesis in parallel to microglia density, activation and cytokine production in the hippocampus compared to other brain regions in the Poly I:C rat model of schizophrenia. We correlated these data with the effects of minocycline treatment on sensorimotor gating deficits – a behavioral phenotype relevant to schizophrenia.

## 2. Materials and methods

### 2.1. Animals

All experimental protocols conformed to the guidelines of the European Communities Council Directive (86/609/EEC) for care of laboratory animals and were approved by the local ethic committee (Landesdirektion Dresden). Wistar Rats (Harlan laboratories) were housed in a temperature and humidity controlled vivarium with a 12-h light–dark cycle (lights on: 6 a.m. to 6 p.m.). They had access to food and water *ad libitum*.

### 2.2. Poly I:C injections

Rats were mated at about an age of three months and the first day after copulation was defined as day one of pregnancy. On gestation day 15, pregnant rats received a single i.v. injection to the tail vein of either Poly I:C (4.0 mg/kg, SIGMA, Germany) dissolved in 200  $\mu$ l 0.9% NaCl, or vehicle (Klein et al., 2013). On postnatal day (PND) 21, pups were weaned and housed by sex and litter and left undisturbed until behavioral phenotyping at PND 90–98. Prior to the experiments rats were handled for about ten minutes daily for three days. Handling comprised habituation to the investigator and the startle chamber. Each experimental group consisted of male subjects derived from multiple independent litters, with no more than three rats from the same litter. The following experimental groups were included into the study: NaCl H<sub>2</sub>O – animals derived from mothers injected with 0.9% NaCl during pregnancy and during treatment period supplied with drinking water. NaCl mino – animals derived from mothers injected with 0.9% NaCl during pregnancy and treated with minocycline added to drinking water. Poly I:C H<sub>2</sub>O – animals derived from mother injected with Poly I:C during pregnancy and during treatment period supplied with drinking water. Poly I:C mino – animals derived from mothers injected with Poly I:C during pregnancy and treated with minocycline added to drinking water.

### 2.3. Minocycline treatment

Minocycline was added to the drinking water from PND 60 until 128, when animals were sacrificed. With an average of 5 ml water intake per 250 g rat per day, the animals received an average daily dosage of 3 mg/kg over the course of approximately 70 days. The daily dosage was adapted from treatments in schizophrenic patients (Levkovitz et al., 2010). Water bottles were changed every second day to ensure minocycline stability.

### 2.4. BrdU injection

Five animals of each group received i.p. injections of 10 mg/ml BrdU at 50 mg/kg body weight for three consecutive days starting at PND 98 to label proliferating cells to be subsequently analyzed for levels of neurogenesis at PND 128.

### 2.5. Immunohistochemistry

The standard procedure for evaluation of cell proliferation and neurogenesis including analysis had been described elsewhere

(Wolf et al., 2011, 2010; Kempermann et al., 2008; Wiskott et al., 2006). Five animals from each group were deeply anesthetized with ketamine and perfused transcardially with cold 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The brains were dissected from the skulls and postfixed overnight. Before sectioning from a dry-ice-cooled copper block on a sliding microtome (Leica, Bensheim, Germany), the hemispheres were transferred to 30% sucrose in 0.1 M phosphate buffer, pH 7.4, until they had sunk. Brains were cut in the coronal plane in 40  $\mu$ m thick sections. The level of generation of new cells was determined by the *in vivo* injection of BrdU, which incorporates during the S-phase into the cell and thus labelled proliferating cells. For BrdU staining, DNA was denatured in 2 N HCl for 30 min at 37 °C. Free-floating sections were then rinsed in 0.1 M borate buffer, pH 8.5, and thoroughly washed in tris-buffered saline (TBS), pH 7.4. To block endogenous peroxidase reactions, sections were pre-treated with 0.6% H<sub>2</sub>O<sub>2</sub>. The anti-BrdU antibody (Sigma) was diluted 1:500 in TBS supplemented with 0.1% TritonX-100, 0.1% Tween 20 and 3% donkey serum (TBS-plus) and the sections were incubated overnight at 4 °C. After rinsing the sections in TBS and a blocking step in TBS-plus, an incubation step with the biotinylated secondary antibody (anti-goat, Abcam) diluted 1:500 in TBS-plus followed. ABC reagent (Vectastain Elite, Vector Laboratories) was applied for one hour at a concentration of 9  $\mu$ l/ml for each reagent. 3, 3'-diaminobenzidine (DAB, Sigma) was used as a chromogen at the concentration of 0.25 mg/ml in TBS with 0.01% H<sub>2</sub>O<sub>2</sub> followed by rinsing with tap water and TBS. We counted the BrdU positive cells in every 6th slice in the gyrus dentatus. We thus analyzed ten slices per brain containing both hemispheres. To estimate the total number of BrdU cells per brain in the gyrus dentatus, we multiplied the counted cells from ten brain sections by six. To phenotype the proliferating cells, we used triple staining for BrdU and a combination of maturation markers as applicable. A total of 50 BrdU-positive cells (five cells distributed across the whole subgranular layer of the gyrus dentatus per each brain section, total of ten sections) per animal were phenotyped. The primary antibodies were applied overnight at 4 °C in the following concentrations: BrdU (1:500, Sigma), anti-Doublecortin (DCX, 1:200, Santa Cruz Biotechnologies), anti-NeuN (1:100, Chemicon). Secondary antibodies were anti-goat, anti-rabbit, anti-mouse (1:250, 2 h RT, Jackson Laboratories) directly coupled to a fluorochrome for confocal analysis. Pictures were taken throughout the entire thickness of the slice containing the dentate gyrus. We used a two-way ANOVA followed by a Bonferroni post-hoc test using Prism 5 for Windows (Graphpad).

## 2.6. Prepulse inhibition (PPI) test

The PPI paradigm is based on the fact that a weak pre-stimulus presented 30–500 ms (ms) before a startling stimulus gates, i.e. reduces the amplitude of the startle response. Acoustic startle reactivity (ASR) and PPI of startle reflex were assessed in a sound-attenuated chamber (41 × 41 × 41 cm) using a movement-sensitive piezoelectric measuring platform connected to a personal computer with an analogue to digital (AD) converter (Startle Response System, TSE, Bad Homburg, Germany) as described previously (Klein et al., 2013; Manahan-Vaughan et al., 2008). During test sessions, animals were placed in a wire mesh cage (22.5 × 8 × 8.5 cm) mounted on the transducer-platform. For acoustic stimulation, two loudspeakers were mounted on both sides of the test cage at a distance of 4 cm. On the days of PPI testing, the animals were transported to the experimental room with the startle-box-room and habituated for 30 min. The experiment consisted of a five minutes acclimatization phase and the test session. During the acclimatization phase, animals received background noise (60 dB sound pressure level (SPL), white noise)

followed by ten initial startle stimuli (100 dB SPL, white noise) lasting each for 20 ms. The test session consisted of seven different trial types delivered in a pseudorandom order: (i) pulse alone (100 dB SPL white noise, 20 ms duration); (ii) control (no stimulus); (iii, iv) prepulse alone (72 dB or 68 dB, pure tone, 10 kHz, 20 ms duration); (v–vii) prepulse (72 dB, 68 dB, or 64 dB) each followed by a pulse with an inter-stimulus interval of 100 ms. A total of ten presentations of each type was given with an inter-trial interval randomized between 20 s and 30 s. Background noise intensity during the whole experiment was 60 dB SPL. The entire test session took about 40 min. PPI was calculated according to the formula  $100 - 100 \times (\text{PPx}/\text{PA})$ , in which PPx is the mean ASR of the 10 PPI trials (separate for each individual prepulse intensity) and PA is the mean ASR to the pulse alone trials. The average PPI response over the three prepulse intensities was analyzed (Klein et al., 2013) and a two-way ANOVA was performed to test for effect of phenotype (Poly I:C) and treatment (minocycline) across the whole session followed by Bonferroni post-hoc tests using Prism 5 for Windows (Graphpad).

## 2.7. Microglia density

Microglia were labelled using goat-anti-Iba1 antibody (1:400, Abcam) in combination with an anti-goat-biotinylated secondary antibody (1:500, Abcam), followed by a HRP conjugated antibody and DAB (Sigma) treatment. Microglia population densities (DAB and light microscopy) in the various regions were estimated using the StereoInvestigator 9 (Mbf Bioscience, 2010), following the Optical Fractioner probe by a person (LFdC) blind to the sample ID. This protocol constitutes an unbiased and efficient method to count cells by systematic-random sampling of a series of sections (40  $\mu$ m thick), from which further estimations can be derived. For our protocol every 12th section was sampled and always in more than five sections (the recommended minimum number to use). Furthermore, the grid size for each animal was estimated for about 25 counting frames and these superimposed counting frames were defined as 111.64  $\mu$ m<sup>2</sup>, consisting of two inclusion dotted lines and two exclusion lines. The counting criterion was the soma of the microglia when it came into focus, which was strictly followed. Lastly, the estimate of precision – the Coefficient of Error (CE) – was always below 0.05, for the population size estimates derived from the counting protocol. For statistical analysis a two-way ANOVA followed by Bonferroni post-hoc tests was performed.

## 2.8. Microglia fluorescence intensity

Microglia were labelled using goat-anti-Iba1 antibody (1:400, Abcam) followed by the secondary antibody anti-goat Cy5 (1:250 Jackson Laboratories) described elsewhere (Vinnakota et al., 2013). For Iba1 reactivity measures (mean fluorescence intensity per area) DAPI was used as reference. The mean fluorescence intensity derived from the image J software for Iba1 were divided by the mean fluorescence intensity of DAPI from the same scan (image J) to assure technical accuracy. From hippocampus (gyrus dentatus) and cerebellum five slices of 20  $\mu$ m thickness per animal were scanned using a confocal microscope (Leica). Z-stacks were analysed using image J software by a person (SAW) blind to the sample identity. We did the statistical analysis using one-way ANOVA and Bonferroni post-hoc test (Prism 5, Windows).

## 2.9. Isolation of microglia

The remaining five animals from each group were also subjected to perfusion with 0.9% NaCl to remove the blood, followed by microglia isolation using the neuronal dissociation kit (Miltenyi,



Bergisch-Gladbach) and pluriBeads™ (pluriSelect, Leipzig). Briefly, the brains were removed, hippocampi and cerebelli extracted and incubated with pre-heated enzyme mix 1 for 15 min at 37 °C in the water bath by inverting the tube several times every five minutes. The tissue was dissociated mechanically using the Pasteur pipette by pipetting up and down ten times followed by two more incubation/dissociation steps with enzyme mix 2 at 37 °C for ten minutes. The single cell suspension was applied on a 30 µm cell strainer placed on 15 ml tube and washed with 10 ml HBSS (w) followed by repeated centrifugation for ten minutes min at 300g and 4 °C and washing steps. Cell pellets were resuspended in buffer and conjugated to CD11b rat pluriBeads-S™ (pluriSelect) according to the manufacturer's instructions. The suspension was sieved down a 15 µm strainer – the pluriBeads™ with CD11b cells stayed on top, the unwanted cells ran through. After detaching, the CD11b cells were collected from the top of the cell strainer and frozen in lysis buffer at –80° until further use. There is a possible effect of the isolation procedure on microglial activation. Nevertheless this kind of activation is not avoidable and will occur across all sample groups. This is why we choose to show relative differences between the groups in cytokine mRNA levels.

#### 2.10. Isolation of neuronal progenitor cells using magnetic activated cell sorting

We used the flow through after the microglia separation step to isolate the neuronal progenitor cells by the MACS technology (Miltenyi Biotec, Bergisch-Gladbach). We incubated the single cell suspension with anti-PSA-NCAM magnetic microBeads™ (Miltenyi Biotec, Bergisch-Gladbach) followed by a magnetic separation of this cell population according to the manufactures protocol. It is noteworthy that in rodent hippocampus PSA-NCAM and Doublecortin expression overlaps 100% (Nacher et al., 2002).

Cell pellets were resuspended in 70 µl MACS buffer consisting of PBS (pH 7.2), 0.5% BSA and 2 mM EDTA, well mixed and incubated for ten minutes at 4 °C. 20 µl of anti-PSA-NCAM micro beads were added, well mixed and incubated for 15 min at 4 °C. Cells were washed with 1–2 ml MACS buffer and centrifuged at 300g and 4 °C for ten minutes. Supernatant was aspirated and cells resuspended in 500 µl MACS buffer. The separation column was placed into the magnetic field of the MACS separator and rinsed with 1 ml MACS buffer. The cell suspension was applied onto the column and washed three times with 500 µl MACS, only adding new buffer when the column reservoir was empty. The column was removed from the separator and placed on a 5 ml tube. 1 ml MACS buffer was used to immediately flush out the labeled cell fraction by pushing the plunger into the column. The cell suspension was transferred into a new tube, centrifuged at 300g for five minutes and immediately resuspended in lysis buffer for RNA extraction (Strattec Molecular, Berlin).

#### 2.11. RNA preparation, RT and qPCR

Total RNA extraction from rat microglia and neuronal progenitor cells was performed with the InviTrap Spin Universal RNA Mini Kit (Strattec Molecular, Berlin) according to the manufacturer's instructions. RNA concentrations were measured with a Nanodrop 1000 (Thermo Fisher Scientific, Waltham) spectrophotometer and stored at –80 °C until further use. First strand cDNA synthesis was done with the SuperScript II reverse transcriptase (Invitrogen, Carlsbad) using oligo-dT primers<sub>12–18</sub> (Invitrogen, Carlsbad) according to the manufacturer's instructions. cDNA samples were stored at –20 °C until further use. Quantitative real-time PCR reactions were done in a 7500 Fast Real-Time thermocycler (Applied Biosystems, Carlsbad) using the SYBR Select Master Mix (Applied Biosystems, Carlsbad) according to the manufacturer's instructions. cDNA input

ranged between 1 and 5 ng/µl of total RNA transcribed into cDNA. The primers used were: 5'-GATCGGTCCCAACAAGGAGG-3' (TNFα fwd); 5'-CAGCTGCTCCTCCGCTT-3' (TNFα rev); 5'-CTGTCTGACCC ATGTGAGCTG-3' (IL-1β fwd); 5'-AGGGATTTTGTCTGTGCTTGTC-3' (IL-1β rev); 5'-CTCTTGGTGACC GGGAGAAG-3' (TNFR1 fwd); 5'-GG TTCCTTTGTGGCACTTGGT-3' (TNFR1 rev); 5'-TAGGACTGG CGAACTGCTTC-3' (TN FR2 fwd); 5'-TCCTGGGATTGTGCATCAGGC-3' (TNFR2 rev); 5'-CCTGCACCA CCAACTGCTTA-3' (GAPDH fwd); 5'-AGT-GATGGCATGGACTGTGG-3' (GAPDH rev). Calculation of the relative expression was done using the comparative Ct (2-ΔΔCt) method with GAPDH as reference gene. Statistical significance was tested using one-way ANOVA followed by Bonferroni post-hoc test.

### 3. Results

#### 3.1. The down regulation of neurogenesis in Poly I:C offspring is normalized by minocycline treatment


To label proliferating cells we injected BrdU i.p. four weeks prior to sacrifice. We counted the BrdU positive cells in the subgranular zone of the dentate gyrus (DG) of the hippocampus and phenotyped them using doublecortin (DXC), a marker of the late mitotic stage and NeuN, a marker of mature neurons (Fig. 1). In line with reports from us and others (Meyer et al., 2010; Wolf et al., 2011), we could detect a decrease in the total number of BrdU positive cells in the Poly I:C H<sub>2</sub>O offspring (2213 ± 141) vs. NaCl H<sub>2</sub>O (3006 ± 94) (Fig. 1A, two-way ANOVA  $F_{3,20} = 20.01$ , Bonferroni post-hoc test  $p \leq 0.001$ ). The decrease in BrdU cells was mainly reflected by the drop in net-neurogenesis measured by BrdU/NeuN double positive cells (Poly I:C H<sub>2</sub>O vs. NaCl H<sub>2</sub>O: 1412 ± 210 vs. 1936 ± 91,  $p \leq 0.001$ ). The pool of more immature neuronal progenitor cells expressing Doublecortin and BrdU was not changed. Thus the pool of mature NeuN expressing neurons was affected by the Poly I:C phenotype. We could rescue the decrease in net-neurogenesis by giving minocycline at PND 60 onwards at a dosage of 3 mg/kg/day (Fig. 1). Minocycline treatment significantly increased the proliferating cells labeled by BrdU (Poly I:C mino: 2852 ± 429,  $p \leq 0.001$ ) and the net-neurogenesis measured by the total number of BrdU/NeuN double positive cells (Poly I:C mino: 1833 ± 276,  $p \leq 0.01$ ). Representative micrographs show the co-labeling of BrdU positive cells (Fig. 1B) with either Doublecortin (1C) or NeuN (1D). Fig. 1F and G show a representative micrograph of BrdU labeled cells for light microscopy that was used for counting the amount of BrdU cells per gyrus dentatus.

#### 3.2. Pre-pulse inhibition deficits are normalized by minocycline treatment


We next aimed to investigate the effects of minocycline on the pre-pulse inhibition of the startle response. We observed a deficit in the pre-pulse inhibition in the Poly I:C offspring (24.5% ± 8.5) compared to the NaCl offspring (40.9% ± 13.6) (Fig. 2, ANOVA  $F_{3,18} = 4.96$ ,  $p = 0.0067$ , Bonferroni post-hoc test  $p \leq 0.05$ ). Minocycline treatment rescued this deficit (Fig. 2, Poly I:C H<sub>2</sub>O vs. Poly I:C mino 24.5% ± 8.5 vs. 41.2% ± 11.59, Bonferroni post-hoc test  $p \leq 0.05$ ).

#### 3.3. Microglia density in most brain regions is not altered in Poly I:C offspring

As a further step we investigated microglia density in different brain regions (ventral striatum (vSt), medial prefrontal cortex (mPFC), nucleus accumbens core (Nacc), cingulate cortex (Cg), gyrus dentatus (DG) and cerebellum (Ce)) since it has been used as a parameter in human post mortem and some animal studies.



**Fig. 1.** Neurogenesis is rescued by minocycline treatment in the Poly I:C model. BrdU-labeled cells were counted in the subgranular zone of the dentate gyrus in the hippocampus to evaluate proliferation. Phenotyping was accomplished via the evaluation of cells double labeled for BrdU and one of the neuronal markers: doublecortin, DCX (late mitotic stage) or NeuN (mature neurons). (A) BrdU positive cells decreased in the Poly I:C H<sub>2</sub>O offspring; mainly reflected in a drop of BrdU/NeuN double positive cells. Error bars indicate standard error means (SEM). Significance levels are denoted by \*\* $p < 0.01$ , \*\*\* $p < 0.001$  based on two-way ANOVA followed by Bonferroni post-hoc test. Representative micrographs are shown from the gyrus dentatus for BrdU (B, red), Doublecortin (C, green) and NeuN (D, blue). In (E) the channels are merged and the arrowheads point to BrdU and NeuN positive cells. To count BrdU cells we used light microscopy and in (F) an overview is shown of a representative section containing the gyrus dentatus (DG). The arrowheads in (G) point to single BrdU labeled cells that were counted by hand by a person blind to the sample identity. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)




**Fig. 2.** Behavioral deficits are rescued by minocycline treatment in the Poly I:C model. The combination of inhibition of the startle response to 120 db pulse for all three pre-pulses (64, 68, 72 db) revealed a deficit in the pre-pulse inhibition in the Poly I:C H<sub>2</sub>O offspring compared to controls (NaCl H<sub>2</sub>O). This effect could be rescued by minocycline-administration. Error bars indicate standard error means (SEM) and significance levels are denoted by \* $p < 0.05$  based on two-way ANOVA followed by Bonferroni post-hoc test.

We could detect a significant increase in microglia density (cells per  $\mu\text{m}^2$ ) in the NAcc of Poly I:C H<sub>2</sub>O ( $3.03 \pm 0.4$ ) compared to NaCl H<sub>2</sub>O ( $2.04 \pm 0.74$ ) (Fig. 3A, two-way ANOVA  $F_{4,156} = 1.8$ , Bonferroni post-hoc test  $p \leq 0.01$ ). There was no significant difference measured in any of the other brain regions mentioned above between these two groups. Moreover there was no significant effect of minocycline treatment detectable (representative micrographs Fig. 3B–I).

#### 3.4. Iba1 reactivity is decreased in Poly I:C offspring but remains unaffected by minocycline treatment in hippocampus and cerebellum

Since microglia density was not significantly changed in the gyrus dentatus, we further analyzed microglia reactivity by measuring the fluorescence intensity of Iba 1 in the gyrus dentatus and cerebellum. In the gyrus dentatus we detected a significant decrease in microglia Iba1 reactivity in the Poly I:C H<sub>2</sub>O group ( $8.8 \pm 0.86$ ) compared to control NaCl H<sub>2</sub>O ( $10.7 \pm 0.83$ ) (Fig. 4A, C and D, ANOVA  $F_{3,20} = 13.52$ ,  $p = 0.0001$ , Bonferroni post-hoc test  $p \leq 0.001$ ). Minocycline had no effect on Iba1 reactivity in the gyrus dentatus (Poly I:C mino  $8.3 \pm 0.59$ ). A similar pattern was seen in the cerebellum: there was a significant decrease in Iba1



**Fig. 3.** Microglia density in Poly I:C model is not affected by minocycline. Microglia density was evaluated in schizophrenia-relevant brain regions (ventral striatum (vSt), cingulate gyrus (Cg), medial prefrontal cortex (mPFC), nucleus accumbens core (NAcc), dentate gyrus of the hippocampus (DG)). We also included the cerebellum (Cereb) as a region unlikely to be affected in schizophrenia. We labeled microglia with Iba1 antibody and visualized the staining using DAB (3, 3'-diaminobenzidine). We evaluated the density using a light microscope (Zeiss) and the StereoInvestigator software. (A) Only in the NAcc of Poly I:C H<sub>2</sub>O we could detect a significant increase in microglia density compared to controls. No significant effect of minocycline treatment was detectable. Error bars indicate standard error means (SEM). Significance levels are denoted by \*\* $p < 0.01$  based on two-way ANOVA followed by Bonferroni post-hoc test. Representative micrographs show the Iba1 staining in NaCl H<sub>2</sub>O animals in the nucleus accumbens core (B), the hippocampus (C) and the cerebellum (D). In (F, G and H) the same brain regions are shown from a brain of the Poly I:C H<sub>2</sub>O group. In (E and I) Iba1 labeled microglia are shown from the cerebellum. LV – lateral ventricle; DG – gyrus dentatus; Cb – 8th cerebellar lobus; aca – anterior commissure, ant.. The dotted lines depict the areas analyzed by the StereoInvestigator software.

reactivity in the Poly I:C H<sub>2</sub>O group ( $1.37 \pm 0.06$ ) compared to control NaCl H<sub>2</sub>O ( $2.77 \pm 0.38$ ) (Fig. 4B, ANOVA  $F_{3,20} = 23.22$ ,  $p \leq 0.0001$ , Bonferroni post-hoc test  $p \leq 0.0001$ ). Minocycline had no effect on Iba1 reactivity in the cerebellum (Poly I:C mino  $0.94 \pm 0.26$ ). Thus neither microglia density nor microglia reactivity measured by Iba1 fluorescence intensity correlated with the pattern seen in the behavior test or neurogenesis.

### 3.5. The production of TNF- $\alpha$ or IL-1 $\beta$ is enhanced in microglia derived from Poly I:C brains in hippocampus, but not cerebellum and this enhancement is attenuated by minocycline treatment

We measured the cytokine production of microglia by mRNA levels in the hippocampus as a more specific functional aspect of microglia activation. We compared hippocampus as a brain region relevant for schizophrenia-like behavior and harboring neurogenesis to microglial cytokine production in the cerebellum, a region not linked to sensorimotor gating performance or neurogenesis. There was no significant change in the microglia derived from the cerebellum in TNF- $\alpha$  or IL-1 $\beta$  mRNA (Fig. 5A).


In the contrary, in the hippocampus we found a significant increase of IL-1 $\beta$  mRNA in the Poly I:C H<sub>2</sub>O ( $1.91 \pm 0.15$ ) compared to NaCl H<sub>2</sub>O ( $0.84 \pm 0.15$ ) (Fig. 5B, ANOVA  $p = 0.003$ ,  $F_{3,16} = 8.24$ , Bonferroni post-hoc test  $p \leq 0.05$ ). In addition we detected a significant effect of minocycline on IL-1 $\beta$  mRNA levels in the Poly I:C mino group ( $0.93 \pm 0.12$ ) compared to Poly I:C H<sub>2</sub>O ( $1.91 \pm 0.15$ , Bonferroni post-hoc test  $p \leq 0.05$ ) in the hippocampus.

The increase in TNF- $\alpha$  mRNA in Poly I:C H<sub>2</sub>O in the hippocampus did not reach significance compared to NaCl H<sub>2</sub>O but was significant higher compared to NaCl mino (Fig. 5B, Poly I:C H<sub>2</sub>O vs. NaCl mino,  $1.39 \pm 0.19$  vs.  $0.78 \pm 0.09$ , ANOVA  $p = 0.009$ ,  $F_{3,17} = 5.9$ , Bonferroni post-hoc test  $p \leq 0.05$ ). Similar to IL-1 $\beta$ , we could measure a decrease of TNF- $\alpha$  in the hippocampus after minocycline treatment (Poly I:C H<sub>2</sub>O vs. Poly I:C mino:  $1.39 \pm 0.19$  vs.  $0.71 \pm 0.07$ , Bonferroni post-hoc test  $p \leq 0.05$ ). We did not detect a significant difference between NaCl H<sub>2</sub>O and NaCl mino. mRNA levels of both pro-inflammatory cytokines were thus down regulated towards control level specifically in the hippocampus by the treatment with minocycline (P60 onwards, 3 mg/kg/day). Therefore the most reliable measure of microglia activation that could be correlated with behavior and neurogenesis in our hands was cytokine mRNA synthesis.

### 3.6. The expression level of TNF- $\alpha$ receptor 2 is decreased in the neuronal progenitor cells derived from hippocampus of Poly I:C offspring and rescued by minocycline treatment

Since it is known that the expression of TNF- $\alpha$  receptor 1 and 2 (TNFR1 and TNFR2) in progenitor cells determines the fate of the cells (apoptosis vs. proliferation), we measured the mRNA level of both receptors in neuronal progenitor cells derived from the hippocampi of all four groups. There was no change in the level of TNFR1 detectable between the groups (Fig. 6A). TNFR2, however, was significantly decreased in the neuronal progenitor cells





**Fig. 4.** Microglial reactivity (Iba1) in Poly I:C is not affected by minocycline. Since microglia density did not show a significant change in the gyrus dentatus we analyzed the microglial reactivity in this region using fluorescence intensity of Iba1 labeling normalized to DAPI fluorescence intensity. Cerebellum was used as a non neurogenic brain region. In the cerebellum (A) as well in the gyrus dentatus (B) a significant decrease in Iba1 reactivity in Poly I:C H<sub>2</sub>O (black bar) was measured compared to controls (white bar). Minocycline did not have an effect in either region on Iba1 reactivity (striped bar, A and B). Significance levels are denoted by \*\*\* $p < 0.01$  and \*\*\*\* $p < 0.001$  based on one-way ANOVA followed by Bonferroni post-hoc test. In panel (C) representative micrographs show the Iba1 (red) and the DAPI (blue) staining from one 20  $\mu$ m Z scan of the gyrus dentatus (DG) from a NaCl H<sub>2</sub>O animal. In panel (D) the same is shown in a section from a Poly I:C H<sub>2</sub>O animal. The dotted line depicts the area that was analyzed for mean fluorescence intensity by the image J software. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

derived from Poly I:C H<sub>2</sub>O ( $0.49 \pm 0.07$ ) vs. NaCl H<sub>2</sub>O ( $1.06 \pm 0.68$ ) (Fig. 6B, ANOVA  $p = 0.0094$ ,  $F_{3,18} = 5.5$ , Bonferroni post-hoc test  $p \leq 0.05$ ). This decrease of TNFR2 in Poly I:C H<sub>2</sub>O was rescued by minocycline treatment in Poly I:C mino (Fig. 6B,  $1.04 \pm 0.17$ ,  $p \leq 0.05$ ).


#### 4. Discussion

Hippocampal adult neurogenesis in the dentate gyrus contributes to brain plasticity with a pool of new neurons, which mature and integrate into functional circuits. We and others have previously shown that adult hippocampal neurogenesis is down-regulated in the offspring of *in utero* immune challenged animals (Wolf et al., 2011; Meyer et al., 2010). Studies conducted on schizophrenic patients reveal smaller hippocampal volume, which correlates with the positive symptoms of schizophrenia, and lower neurogenesis in these patients (Kühn et al., 2012; Reif et al., 2006). Decreased adult hippocampal neurogenesis leads to several cognitive deficits also in rodents (Biscaro et al., 2012). Low neurogenesis levels probably contribute to disruptions in sensorimotor gating, since the hippocampus is one of the areas implicated in the circuitry of this behavioral measure (Kühn et al., 2012; Kumari et al., 2007; Swerdlow and Geyer, 1998). In the Poly I:C offspring, we confirm the decrease in net-neurogenesis and the altered


behavioral phenotype in the PPI. Moreover we could show that minocycline treatment rescued neurogenesis and attenuated the altered behavioral phenotype when given from PND 60 onwards at a dosage of 3 mg/kg/day for approximately ten weeks. The minocycline treatment itself did not affect hippocampal neurogenesis when given to control rats.

It has been shown that microglia have a role in the normal physiological guidance of adult neurogenesis in the hippocampus (Gebara et al., 2013). Moreover, microglial mediated inflammation can be detrimental for hippocampal neurogenesis (reviewed in Kohman and Rhodes, 2013; Ekdahl et al., 2009). In addition, treatment with anti-inflammatory agents including minocycline in mouse models of sickness behavior and Alzheimer's disease, have restored hippocampal neurogenesis (Biscaro et al., 2012; Monje et al., 2003). In our present study we show similar effects of minocycline on hippocampal neurogenesis in the rat model of schizophrenia. Taken together these findings strengthen the idea of a negative influence of activated microglia on neurogenesis and the ability of anti-inflammatory drugs to reverse this effect.

Human studies suggested an increase in the density of reactive microglia in the hippocampus of schizophrenia patients (for review see Frick et al., 2013). However, in the young adult offspring of Poly I:C exposed pregnant dams, the density of microglia was not different (Garay et al., 2013). We could confirm this observation in the hippocampus, the medial prefrontal cortex, the ventral



**Fig. 5.** Hippocampus specific increase in microglial cytokines is rescued by minocycline. Calculation of the relative expression of IL-1 $\beta$  and TNF- $\alpha$  was done using the comparative Ct (2- $\Delta\Delta$ Ct) method with GAPDH as reference gene. No changes in cytokine levels was seen in the cerebellum (A). A significant increase of IL-1 $\beta$  was measured in the hippocampus in Poly I:C H<sub>2</sub>O compared to NaCl H<sub>2</sub>O. This increase was brought back towards baseline expression in the Poly I:C mino group. A similar regulation was seen in the level of TNF- $\alpha$  mRNA, where minocycline had a significant effect in the Poly I:C mino group as well. The increase in TNF- $\alpha$  in Poly I:C H<sub>2</sub>O is not significant compared to NaCl H<sub>2</sub>O but was significant to NaCl mino. There is no significant difference between NaCl H<sub>2</sub>O and NaCl mino. Error bars indicate standard error means (SEM). Significance levels are denoted by \* $p$  < 0.05 and \*\* $p$  < 0.01 based on one-way ANOVA followed by Bonferroni post-hoc test.



**Fig. 6.** Decreased expression of TNFR2 on hippocampal neuronal progenitor cells is rescued by minocycline. Calculation of the relative expression of TNFR1 and TNFR2 was done using the comparative Ct (2- $\Delta\Delta$ Ct) method with GAPDH as reference gene. No change in TNFR1 mRNA expression level was detected between the groups. TNFR2 mRNA level was significantly decreased in the Poly I:C H<sub>2</sub>O group compared to NaCl H<sub>2</sub>O. This decrease was brought back to control level by minocycline treatment (Poly I:C mino). Significance levels are denoted by \* $p$  < 0.05 based on one-way ANOVA followed by Bonferroni post-hoc test.

striatum, the cingulate cortex and the cerebellum with the exception of the nucleus accumbens. Another study showed increased microglia density in aged Poly I:C offspring (PND 180) in hippocampus, corpus callosum, pons and thalamus (van den Eynde et al., 2014). We propose that the nucleus accumbens might be a region where density differences in microglia become evident in the Poly I:C model around the age of four months while the process may take longer in other brain regions. Variations in age between the animals used in different studies might explain the controversial findings regarding microglia density. It is worthwhile to note, that in our study and in the study conducted by Garay et al. Iba1 was used to label microglia, while van den Eynde used OX42 and

ED-1. Moreover, we used the Stereoinvestigator tool to analyze microglial density and these technical differences may account for the different findings. Minocycline had no effect on microglia density in any of the brain regions tested. This suggests that Poly I:C exposure during pregnancy does not necessarily lead to an increased microglial density in early adulthood when behavior symptoms are already evident, while it might become important in later age. We therefore tested functional parameters of these microglial cells and focused on the hippocampus as one of the regions of adult neurogenesis.

We found that IL-1 $\beta$  and TNF- $\alpha$  are upregulated in the Poly I:C offspring compared to either one or both of the control NaCl

offspring groups indicating that microglia are chronically activated in this animal model of schizophrenia. This is in line with other studies that reported an increased level of pro-inflammatory cytokines in the brain of the adult Poly I:C offspring (Garay et al., 2013) and in the brain of fetuses after a maternal immune activation (Arrode-Brusés and Brusés, 2012; Smith et al., 2007; Giovanoli et al., 2013).

Minocycline given from PND 60 onwards attenuated the microglial pro-inflammatory cytokine production in the hippocampus paralleled by the restored deficits in sensorimotor gating and neurogenesis. This suggests that the role of microglia cells is not limited to a transient embryonic activation since features of microglial activation can also be affected in the adulthood by treating with minocycline. This is in line with findings where treatment with valproic acid suppressed glial proliferation in the Disc1-L100P mutant mice – a genetic model of schizophrenia (Lipina et al., 2012). Our data support the mild-encephalitis hypothesis where it is stated that an ongoing inflammatory state is the underlying cause of the disease (Bechter, 2013a,b). We could infer that a more activated microglial phenotype reflected by an increase in IL-1 $\beta$  and TNF- $\alpha$  in the Poly I:C exposed offspring might affect neurogenesis. Two recent studies indicated that IL-1 $\beta$  has a direct and negative effect on adult hippocampal neurogenesis independent of IL-1 $\beta$  receptor signaling (Wu et al., 2013; Choi and Friedman, 2014). A study conducted in the lab of Palmer (Chen and Palmer, 2013) concludes that TNF- $\alpha$  directly and differentially affects NPC's proliferation through activation of TNF-receptor 1 and 2 (TNFR1 and 2) thereby inducing a homeostatic regulation of adult neurogenesis. At baseline levels it promotes neurogenesis through TNFR2 and it inhibits it through TNFR1. Under pathological conditions, when higher levels of TNF- $\alpha$  are produced the TNFR1 signaling may overrule and induce apoptosis of precursor cells (Chen and Palmer, 2013). We have found that TNFR2 mRNA is down regulated in Poly I:C NPCs. Since signaling through TNFR2 promotes proliferation of NPCs, it is conceivable that neurogenesis is impaired in the animal model of schizophrenia at least partially due to the down regulation of this receptor. It might also be possible, that due to the down regulation of TNFR2, TNFR1 signaling may overrule and induce apoptosis similar to the *in vitro* situation described by Chen and colleagues.

The minocycline treatment normalized TNFR2 expression levels in the NPCs, rescued net-neurogenesis, attenuated the levels of TNF- $\alpha$  and IL-1 $\beta$  in hippocampus-derived microglia and the deficit in sensory motor gating. Since minocycline had no effect on the TNFR2 expression levels in the NPCs derived from the hippocampi of NaCl offspring per se, we propose that the mode of action of minocycline is promoted through the regulation of microglial derived TNF- $\alpha$  and IL-1 $\beta$ . In human patients minocycline had beneficial effects at a similar dosage as we have used in our study (Levkovitz et al., 2010). In a recent *in vitro* study it was shown that minocycline inhibited the production of TNF- $\alpha$  from IFN- $\gamma$ -activated microglia (Seki et al., 2013). Our data support the use of minocycline as an add on therapy in schizophrenic patients. Moreover we provide evidence for the mode of action of minocycline on neurobiological factors such as microglia cytokine production and neuronal progenitor cell TNFR expression that contribute to a mild chronic inflammatory state in the brain and lead to lower neuronal plasticity constituting endophenotypes in an animal model of schizophrenia.

## Acknowledgments

The authors are grateful for excellent technical assistance by Sophie Neuber, Doris Zschaber and Nadine Scharek. The work was supported by the by BMBF under the framework of EraNet

Neuron (DBS F20\_rat) and the German research council (DFG) through SFB TR 43.

## References

- Abazyan, B., Nomura, J., et al., 2010. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. *Biol. Psychiatry*. 68 (12), 1172–1181.
- Altman, J., Das, G.D., 1965. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. *J. Comp. Neurol.* 124 (3), 319–335.
- Arrode-Brusés, G., Brusés, J.S., 2012. Maternal immune activation by Poly I: C induces expression of cytokines IL-1 $\beta$  and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. *J. Neuroinflammation* 9, 83.
- Bechter, K., 2013a. Updating the mild encephalitis hypothesis of schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry*. 42, 71–91.
- Bechter, K., 2013b. Schizophrenia – a mild encephalitis? *Fortschr. Neurol. Psychiatr.* 81 (5), 250–259.
- Biscaro, B. et al., 2012. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. *Neurodegener. Dis.* 9 (4), 187–198.
- Blank, T., Prinz, M., 2013. Microglia as modulators of cognition and neuropsychiatric disorders. *Glia* 61 (1), 62–70.
- Brown, A.S., Derkits, E.J., 2010. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. *Am. J. Psychiatry*. 167 (3), 261–280.
- Brown, A.S. et al., 2004. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. *Am. J. Psychiatry*. 161 (5), 889–895.
- Bruehl-Jungerman, E. et al., 2007. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. *Rev. Neurosci.* 18 (2), 93–114.
- Buka, S.L. et al., 2001. Maternal cytokine levels during pregnancy and adult psychosis. *Brain Behav. Immun.* 15 (4), 411–420.
- Busse, S. et al., 2012. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? *Brain Behav. Immun.* 26 (8), 1273–1279.
- Chen, Z., Palmer, T.D., 2013. Differential roles of TNFR1 and TNFR2 signaling in adult hippocampal neurogenesis. *Brain Behav. Immun.* 30, 45–53.
- Choi, S., Friedman, W.J., 2014. Interleukin-1 $\beta$  enhances neuronal vulnerability to proNGF-mediated apoptosis by increasing surface expression of p75<sup>NTR</sup> and sortilin. *J. Neurosci.* 257, 11–19. <http://dx.doi.org/10.1016/j.neuroscience.2013.10.058>. 5, 2013 – 2014, 307–15.
- Dean, O.M. et al., 2012. Minocycline: therapeutic potential in psychiatry. *CNS Drugs* 26 (5), 391–401.
- Deng, W. et al., 2010. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? *Nat. Rev. Neurosci.* 11 (5), 339–350.
- Ekdahl, C.T. et al., 2009. Brain inflammation and adult neurogenesis: the dual role of microglia. *Neuroscience* 158 (3), 1021–1029.
- Eriksson, P.S. et al., 1998. Neurogenesis in the adult human hippocampus. *Nat. Med.* 4 (11), 1313–1317.
- Ewing, S.G., Winter, C., 2013. The ventral portion of the CA1 region of the hippocampus and the prefrontal cortex as candidate regions for neuromodulation in schizophrenia. *Med. Hypotheses* 80 (6), 827–832.
- Falkai, P. et al., 1999. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. *Neuropathol. Appl. Neurobiol.* 25 (1), 48–53.
- Feldon, J., Weiner, I., 2009. Editorial: special issue on modeling schizophrenia. *Behav. Brain Res.* 204 (2), 255–257.
- Fineberg, A.M., Ellman, L.M., 2013. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. *Biol. Psychiatry*. 73 (10), 951–966.
- Floresco, S.B., Jentsch, J.D., 2011. Pharmacological enhancement of memory and executive functioning in laboratory animals. *Neuropsychopharmacology* 36 (1), 227–250.
- Frick, L.R. et al., 2013. Microglial dysregulation in psychiatric disease. *Clin. Dev. Immunol.* 2013, 608654.
- Fricker, M. et al., 2013. Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia. *J. Biol. Chem.* 288 (13), 9145–9152.
- Gal, G. et al., 2009. Enhancement of latent inhibition in patients with chronic schizophrenia. *Behav. Brain Res.* 197 (1), 1–8.
- Garay, P.A. et al., 2013. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. *Brain Behav. Immun.* 31, 54–68.
- Gebara, E. et al., 2013. Adult hippocampal neurogenesis inversely correlates with microglia in conditions of voluntary running and aging. *Front. Neurosci.* 7, 145.
- Gilmoe, J.H., Jarskog, L.F., 1997. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. *Schizophr. Res.* 24 (3), 365–367.
- Giovanoli, S. et al., 2013. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. *Science* 339 (6123), 1095–1099.
- Harrison, P.J., 2004. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. *Psychopharmacol. (Berl)* 174 (1), 151–162.
- Harry, G.J., Kraft, A.D., 2012. Microglia in the developing brain: a potential target with lifetime effects. *Neurotoxicology* 33 (2), 191–206.
- Juckel, G. et al., 2011. Microglial activation in a neuroinflammatory animal model of schizophrenia—a pilot study. *Schizophr. Res.* 131 (1–3), 96–100.

- Kempermann, G. et al., 2008. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. *Curr. Opin. Psychiatry*. 21 (3), 290–295.
- Kirkpatrick, B., 2013. Understanding the physiology of schizophrenia. *J. Clin. Psychiatry*. 74 (3), e05.
- Klein, J. et al., 2013. Mapping brain regions in which deep brain stimulation affects schizophrenia-like behavior in two rat models of schizophrenia. *Brain Stimul.* 6 (4), 490–499.
- Kohman, R.A., Rhodes, J.S., 2013. Neurogenesis, inflammation and behavior. *Brain Behav. Immun.* 27 (1), 22–32.
- Kühn, S. et al., 2012. Hippocampal subfields predict positive symptoms in schizophrenia: first evidence from brain morphometry. *Transl. Psychiatry*. 2, e127.
- Kumari, V. et al., 2007. A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. *Int. J. Neuropsychopharmacol.* 10 (4), 463–477.
- Kumari, V. et al., 2008. Cortical grey matter volume and sensorimotor gating in schizophrenia. *Cortex* 44 (9), 1206–1214.
- Levkovitz, Y. et al., 2010. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. *J. Clin. Psychiatry*. 71 (2), 138–149.
- Lipina, T.V. et al., 2012. Prophylactic valproic acid treatment prevents schizophrenia related behaviour in Disc1-L100P mutant mice. *PLoS One* 7 (12), e51562.
- Lipina, T.V. et al., 2013. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. *J. Neurosci.* 33 (18), 7654–7666.
- Lipska, B.K., 2004. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. *J. Psychiatry. Neurosci.* 29 (4), 282–286.
- Manahan-Vaughan, D. et al., 2008. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. *Hippocampus* 18 (2), 125–134.
- Mednick, S.A. et al., 1988. Adult schizophrenia following prenatal exposure to an influenza epidemic. *Arch. Gen. Psychiatry*. 45 (2), 189–192.
- Meyer, U., 2013. Developmental neuroinflammation and schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry*. 42, 20–34.
- Meyer, U., 2014. Prenatal Poly (I:C) exposure and other developmental immune activation models in rodent systems. *Biol. Psychiatry*. 75 (4), 307–315.
- Meyer, U., Feldon, J., 2012. To poly (I:C) or not to poly (I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. *Neuropharmacology* 62 (3), 1308–1321.
- Meyer, U. et al., 2005. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. *Neurosci. Biobehav. Rev.* 29 (6), 913–947.
- Meyer, U. et al., 2010. Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. *Psychopharmacol. (Berl)* 208 (4), 531–543.
- Miyaoka, T. et al., 2008. Minocycline as adjunctive therapy for schizophrenia: an open-label study. *Clin. Neuropharmacol.* 31 (5), 287–292.
- Monje, M.L. et al., 2003. Inflammatory blockade restores adult hippocampal neurogenesis. *Science* 302 (5651), 1760–1765.
- Müller, N., Schwarz, M.J., 2010. Immune system and schizophrenia. *Curr. Immunol. Rev.* 6 (3), 213–220.
- Nacher, J. et al., 2002. Distribution of PSA-NCAM expression in the amygdala of the adult rat. *Neuroscience* 113 (3), 479–484.
- Nyffeler, M. et al., 2006. Maternal immune activation during pregnancy increases limbic GABA<sub>A</sub> receptor immunoreactivity in the adult offspring: implications for schizophrenia. *Neuroscience* 143 (1), 51–62.
- Ozawa, K. et al., 2006. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. *Biol. Psychiatry*. 59 (6), 546–554.
- Piontkewitz, Y. et al., 2011a. Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat. *Biol. Psychiatry*. 70 (9), 842–851.
- Piontkewitz, Y. et al., 2011b. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. *Schizophr. Bull.* 37 (6), 1257–1269.
- Piontkewitz, Y. et al., 2012. Tracing the development of psychosis and its prevention: what can be learned from animal models. *Neuropharmacology* 62 (3), 1273–1289.
- Reif, A. et al., 2006. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. *Mol. Psychiatry*. 11 (5), 514–522.
- Schwarzkopf, S.B. et al., 1992. Sensory gating in rats depleted of dopamine as neonates: potential relevance to findings in schizophrenic patients. *Biol. Psychiatry*. 31 (8), 759–773.
- Seki, Y. et al., 2013. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-gamma-stimulated microglia in co-culture model. *Schizophr. Res.* 151 (1–3), 20–28.
- Shi, L. et al., 2003. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. *J. Neurosci.* 23 (1), 297–302.
- Sierra, A. et al., 2010. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell* 7 (4), 483–495.
- Smith, S.E. et al., 2007. Maternal immune activation alters fetal brain development through interleukin-6. *J. Neurosci.* 27 (40), 10695–10702.
- Steiner, J. et al., 2006. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. *Acta Neuropathol.* 112 (3), 305–316.
- Swerdlow, N.R., Geyer, M.A., 1998. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. *Schizophr. Bull.* 24 (2), 285–301.
- van Berckel, B.N. et al., 2008. Microglia activation in recent-onset schizophrenia: a quantitative (R)[11C]PK11195 positron emission tomography study. *Biol. Psychiatry*. 64 (9), 820–822.
- van den Eynde, K. et al., 2014. Hypolocomotive behaviour associated with increased microglia in prenatal immune activation model with relevance to schizophrenia. *Behav. Brain Res.* 258, 179–186.
- Vinnakota, K. et al., 2013. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. *Neuro. Oncol.* 15 (11), 1457–1468.
- Wexler, B.E. et al., 2009. Neuropsychological near normality and brain structure abnormality in schizophrenia. *Am. J. Psychiatry*. 166 (2), 189–195.
- Winter, C. et al., 2008. Dopamine and serotonin levels following prenatal viral infection in mouse-implications for psychiatric disorders such as schizophrenia and autism. *Eur. Neuropsychopharmacol.* 18 (10), 712–716.
- Wiskott, L. et al., 2006. A functional hypothesis for adult hippocampal neurogenesis: avoidance of catastrophic interference in the dentate gyrus. *Hippocampus* 16 (3), 329–343.
- Wolf, S.A. et al., 2010. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. *Cell Commun. Signal.* 8, 12.
- Wolf, S.A. et al., 2011. Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia. *Brain Behav. Immun.* 25 (5), 971–980.
- Wu, M.D. et al., 2013. Sustained IL-1 $\beta$  expression impairs adult hippocampal neurogenesis independent of IL-1 signaling in nestin<sup>+</sup> neural precursor cells. *Brain Behav. Immun.* 32, 9–18.
- Yamada, S., 2000. Disruption of prepulse inhibition of acoustic startle as an animal model for schizophrenia. *Nihon Shinkei Seishin Yakurigaku Zasshi* 20 (4), 131–139.
- Zuckerman, L., Weiner, I., 2005. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. *J. Psychiatr. Res.* 39 (3), 311–323.
- Zuckerman, L. et al., 2003. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. *Neuropsychopharmacology* 28 (10), 1778–1789.

My curriculum vitae does not appear in the electronic version of my paper for reasons of data protection

My curriculum vitae does not appear in the electronic version of my paper for reasons of data protection

My curriculum vitae does not appear in the electronic version of my paper for reasons of data protection



# List of publications

**Daniele Mattei**, Andranik Ivanov, Philipp Jordan, Dilansu Guneykaya, Eric Bodekke, Bart Eggen, Wandert Schaafsma, Ana Pombo, Carmelo Ferrai, Bozena Kaminska, Piotr Przanowski, Helmut Kettenmann and Susanne A. Wolf. Long lasting changes in microglia cell transcriptome and function following gestational maternal immune activation accompanies behavioral deficits in a mouse model of schizophrenia. **In preparation.**

Luisa Möhle\*, **Daniele Mattei**\*, Markus M.Heimesaat\*, Stefan Bereswill, André Fischer, Marie Alutis, Dolores Hambardzumyan, Polly Matzinger, Ildiko R. Dunay and Susanne A. Wolf. Ly6C<sup>hi</sup> monocytes provide a link between antibiotic-induced changes in gut microbiota and adult hippocampal neurogenesis. In revision in Cell Reports.

**Mattei D**, Schweibold R, Wolf SA. Brain in flames – Animal models of schizophrenia: utility and limitations. Neuropsychiatric Disease and Treatment. 2015.

**Mattei D**\*, Djodari-Irani A\*, Hadar R, Pelz A, de Cossío LF, Goetz T, Matyash M, Kettenmann H, Winter C, Wolf SA. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav Immun. 2014



Janelidze S, **Mattei D**, Westrin Å, Träskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011

# Acknowledgements

First of all I would like to thank Professor Helmut Kettenmann for allowing me to pursue this exciting project in his lab. I would also thank my supervisor Dr. Susanne A Wolf for making this journey a very beautiful one! Sus, I learned from you a lot. Also I would like to thank Sophie Neuber, the technical assistant who followed me for two wonderful years. Sophie, you are a great person to work with, and I thank you deeply for all your help. I would like to thank also my former and present colleagues and friends who helped me and sustained me during my PhD (Maria Pannell, Felipe Sassi, Frank Szulzewsky, Philipp Jordan, Nadine Richter, Petya Georgieva, Kristin Stock, Katyani Vinnakota, Feng Who, Dong Le, Alice Buonfiglioli, Emile Wogram, Stefan Wendt, Omar Dyze, Martin Merch, Amanda Costa, Dilansu Guneykaya, Martin Mersch). Guys, you made my life in the lab and in Berlin a better one. I would also like to thank the technical assistants of the lab Regina Piske, Nadine Scharek, Michaela Segeer-Zografakis, they have been very helpful and patient. Many thanks goes to the administrative assistant of the lab Birgit Jarchow, who helped me and assisted me so many times! Birgit you are a wonderful person! Also many thanks goes to Professor Christine Winter, Professor Eric Boddeke and Professo Bozena Kaminska and their respective groups. They opened their labs for me to learn new techniques and helped me in my projects. Moreover, I would like to thank my brother in law Andranik Ivanov for his support during my time in Berlin. Man, you made this journey a wonderful one! Finally I would like to thank my family who helped me and sustained me during my PhD and have always been there for me.